OncoMatch/Clinical Trials/NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Is NCT05006716 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies BGB-16673 for b-cell malignancy.
Treatment: BGB-16673 — Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton tyrosine kinase inhibitor — any line of therapy
Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance)
Must have received: Bruton tyrosine kinase inhibitor — any line of therapy
discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance
Must have received: Bruton tyrosine kinase inhibitor — Phase 2 Cohorts in R/R CLL/SLL, R/R MCL, and R/R WM
Participants who previously received a BTKi are eligible if they had disease progression on only one regimen containing a covalent BTKi. Note: Participants may have received treatment with ≥ 2 different covalent BTKis if additional BTKis were discontinued secondary to an event other than disease progression.
Must have received: Bruton tyrosine kinase inhibitor — MCL expansion cohorts (Phase 2)
participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy
Must have received: Bruton tyrosine kinase inhibitor — CLL/SLL expansion cohorts (Phase 2)
CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Must have received: Bcl-2 inhibitor — CLL/SLL expansion cohorts (Phase 2)
CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- Mayo Clinic Phoenix · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- University of Arizona Cancer Center · Tucson, Arizona
- University of California San Diego (Ucsd) Moores Cancer Center · La Jolla, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05006716 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received Bruton tyrosine kinase inhibitor and Bruton tyrosine kinase inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify